Innate Pharma (IPHA) Q3 2025 Earnings Call Summary

1Key Financial Results and Metrics

Cash Position: Innate Pharma ended Q3 2025 with a cash balance of EUR 56.4 million, expected to fund operations through Q3 2026.

2Strategic Updates and Business Highlights

Lacutamab: Received FDA clearance to initiate the TELLOMAK-3 Phase III trial for cutaneous T-cell lymphoma (CTCL), targeting accelerated approval for Sézary syndrome based on promising Phase II data.

Clinical Pipeline: Focused on three key assets:

IPH4502: A differentiated antibody-drug conjugate (ADC) targeting Nectin-4, showing early signs of clinical activity in ongoing trials.

Monalizumab: Collaborating with AstraZeneca, the PACIFIC-9 Phase III trial is fully enrolled, with data expected in H2 2026.

Lacutamab: Positioned as a potential game changer in CTCL, with plans to expand its use in mycosis fungoides and peripheral T-cell lymphoma.

Commercial Strategy: Aimed at establishing lacutamab as a preferred therapy in CTCL, with a focus on specialized treatment centers.

3Forward Guidance and Outlook

Lacutamab: Anticipated to initiate the confirmatory Phase III trial in H1 2026, with a potential BLA submission for Sézary syndrome expected in early 2027.

IPH4502: Completion of the dose escalation phase of trials expected by early 2026, with data on clinical activity anticipated.

Monalizumab: Positive expectations for PACIFIC-9 trial results based on previous studies, with data expected in late 2026.

4Bad News, Challenges, or Points of Concern

Regulatory Risks: While FDA has provided a pathway for accelerated approval for lacutamab, any delays in trial initiation or enrollment could impact timelines.

Market Competition: The competitive landscape for CTCL therapies could pose challenges, particularly with existing treatments like mogamulizumab.

Partnership Discussions: The company is still exploring potential partnerships, which may be influenced by the need for FDA protocol acceptance.

5Notable Q&A Insights

Commercial Launch for Lacutamab: Key preparations include ensuring inclusion in NCCN guidelines for Sézary syndrome and mycosis fungoides prior to BLA submission.

Data Expectations for IPH4502: Aiming to demonstrate clinical activity in PADCEV-resistant settings, with plans for adaptive study designs to explore signals in various tumor types.

KOL Feedback: Positive momentum from key opinion leaders regarding lacutamab's potential, with expectations that it may become a preferred second-line treatment in mycosis fungoides.

Manufacturing Readiness: The company is prepared for commercial-scale manufacturing of lacutamab, which will not be a bottleneck for BLA submission. This summary encapsulates the key points from Innate Pharma's Q3 2025 earnings call, highlighting both the strategic advancements and potential challenges the company faces moving forward.